Companies › ADC Therapeutics
1 active drug program in 18 registered trials: 12 Phase 2, 5 Phase 1, 1 Phase 3; Oncology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Loncastuximab Tesirine B-lymphocyte antigen CD19 binding agent | CD19 | Phase 3 | Relapsed Diffuse Large B-Cell Lymphoma; B-Cell Non-Hodgkin Lymphoma; Relapsed or Refractory Large B-cell Lymphoma; Relapsed Mantle Cell Lymphoma … | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05053659 | Loncastuximab Tesirine | Phase 1 | Relapsed Non Hodgkin Lymphoma | Oncology | Nov 2026 |
| NCT05971251 | Loncastuximab Tesirine | Phase 1 | Chronic Lymphocytic Leukemia | Oncology | Dec 2026 |
| NCT06788964 | Loncastuximab Tesirine | Phase 2 | Relapsed or Refractory Large B-cell Lymphoma | Oncology | Mar 2027 |
| NCT05249959 | Loncastuximab Tesirine | Phase 2 | Relapsed Mantle Cell Lymphoma | Oncology | Mar 2027 |
| NCT04970901 | Loncastuximab Tesirine | Phase 1 | B-Cell Non-Hodgkin Lymphoma | Oncology | Mar 2027 |
| NCT06918912 | Loncastuximab Tesirine | Phase 2 | Diffuse Large B-Cell Lymphoma | Oncology | Jun 2027 |
| NCT04998669 | Loncastuximab Tesirine | Phase 2 | Follicular Lymphoma | Oncology | Aug 2027 |
| NCT05270057 | Loncastuximab Tesirine | Phase 1 | B-cell Lymphoma | Oncology | Oct 2027 |
| NCT05600686 | Loncastuximab Tesirine | Phase 2 | Double-Expressor Lymphoma | Oncology | Dec 2027 |
| NCT04384484 | Loncastuximab Tesirine | Phase 3 | Relapsed Diffuse Large B-Cell Lymphoma | Oncology | Jun 2028 |
| NCT05296070 | Loncastuximab Tesirine | Phase 2 | Marginal Zone Lymphoma | Oncology | Jun 2028 |
| NCT05190705 | Loncastuximab Tesirine | Phase 2 | Waldenstrom Macroglobulinemia | Oncology | Aug 2028 |
| NCT05672251 | Loncastuximab Tesirine | Phase 2 | Recurrent Diffuse Large B-Cell Lymphoma | Oncology | Aug 2029 |
| NCT06607549 | Loncastuximab Tesirine | Phase 1 | Central Nervous System Lymphoma | Oncology | Nov 2029 |
| NCT05464719 | Loncastuximab Tesirine | Phase 2 | Large B-cell Lymphoma | Oncology | Jan 2030 |
| NCT07197307 | Loncastuximab Tesirine | Phase 2 | Aggressive Diffuse Large B-cell Lymphoma | Oncology | Apr 2030 |
| NCT06919939 | Loncastuximab Tesirine | Phase 2 | Large B-cell Lymphoma | Oncology | Jan 2031 |
| NCT05991388 | Loncastuximab Tesirine | Phase 2 | B-cell Non Hodgkin Lymphoma | Oncology | May 2031 |
Cash of $189m on 2026-09-30; operating cash outflow about $93m a year; runway about 24 months at that burn, to Oct 2028; 6 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Immutep S.A.S. Candel Therapeutics Shanghai Ming Ju Biotechnology Actinium Pharmaceuticals Maia Biotechnology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.